MX2021012604A - Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas. - Google Patents

Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.

Info

Publication number
MX2021012604A
MX2021012604A MX2021012604A MX2021012604A MX2021012604A MX 2021012604 A MX2021012604 A MX 2021012604A MX 2021012604 A MX2021012604 A MX 2021012604A MX 2021012604 A MX2021012604 A MX 2021012604A MX 2021012604 A MX2021012604 A MX 2021012604A
Authority
MX
Mexico
Prior art keywords
treatment
viral
inhibitor
bacterial infections
novel mek
Prior art date
Application number
MX2021012604A
Other languages
English (en)
Inventor
Oliver Planz
Original Assignee
Atriva Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atriva Therapeutics Gmbh filed Critical Atriva Therapeutics Gmbh
Publication of MX2021012604A publication Critical patent/MX2021012604A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención se refiere a PD-0184264 para uso en un método para el tratamiento de una infección viral o una coinfección viral y bacteriana. También se proporcionan composiciones que comprenden estos inhibidores para uso en el tratamiento de una infección por virus y la prevención y/o tratamiento de una coinfección bacteriana.
MX2021012604A 2019-04-16 2020-04-16 Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas. MX2021012604A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LU101183A LU101183B1 (en) 2019-04-16 2019-04-16 Novel mek-inhibitor for the treatment of viral and bacterial infections
PCT/EP2020/060692 WO2020212478A1 (en) 2019-04-16 2020-04-16 Novel mek-inhibitor for the treatment of viral and bacterial infections

Publications (1)

Publication Number Publication Date
MX2021012604A true MX2021012604A (es) 2021-11-12

Family

ID=66554457

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012604A MX2021012604A (es) 2019-04-16 2020-04-16 Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.

Country Status (12)

Country Link
US (1) US20220193017A1 (es)
EP (1) EP3955908A1 (es)
JP (1) JP2022529343A (es)
KR (1) KR20210153642A (es)
CN (1) CN114007598A (es)
AU (1) AU2020258002A1 (es)
BR (1) BR112021020605A2 (es)
CA (1) CA3136171A1 (es)
EA (1) EA202192454A1 (es)
LU (1) LU101183B1 (es)
MX (1) MX2021012604A (es)
WO (1) WO2020212478A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4186500A1 (en) * 2021-11-24 2023-05-31 Atriva Therapeutics GmbH Mek inhibitors for the prevention and treatment of long covid syndrome
WO2024042050A1 (en) * 2022-08-22 2024-02-29 Atriva Therapeutics Gmbh Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10017480A1 (de) 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
CN105101999B (zh) 2012-10-08 2018-07-17 归属疗法有限公司 用在病毒性疾病的治疗中的mek抑制剂
CN116942832A (zh) 2014-05-16 2023-10-27 归属疗法有限公司 抗流感病毒和金黄色葡萄球菌合并感染的新型抗感染策略

Also Published As

Publication number Publication date
BR112021020605A2 (pt) 2021-12-07
LU101183B1 (en) 2020-10-16
EA202192454A1 (ru) 2022-03-22
WO2020212478A1 (en) 2020-10-22
CN114007598A (zh) 2022-02-01
AU2020258002A1 (en) 2021-11-18
US20220193017A1 (en) 2022-06-23
JP2022529343A (ja) 2022-06-21
CA3136171A1 (en) 2020-10-22
KR20210153642A (ko) 2021-12-17
EP3955908A1 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
PH12018501962A1 (en) Stablizied soluble pre-fusion rsv f proteins
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
MX2019002978A (es) Composiciones que comprenden una bacteria no patogena y metodos para proteger plantas y animales anfitriones contra enfermedades micoticas, bacterianas y virales.
GEP20227374B (en) Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
EP3846846A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRUS INFECTION
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
AU2012332832A8 (en) Compositions useful for the treatment of viral diseases
MX2021007602A (es) Derivados de heteroarildihidropirimidina y metodos de tratamiento de infecciones de hepatitis b.
MX2022014561A (es) Inhibidores de mek para el tratamiento o prevencion de infecciones por coronavirus y/o tormenta de citocinas por covid-19.
EP4025256A4 (en) COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
MX2018002707A (es) Derivados de tetrahidrofurano antivirales.
MX2021012604A (es) Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.
MX2019009964A (es) Nuevo bacteriofago de clostridium perfringens clo-pep-2 y uso para inhibir la proliferacion de clostridium perfringens.
EP3930724A4 (en) METHOD AND COMPOSITION FOR INHIBITING VIRAL INFECTION
EP4037706A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION
MX2022016066A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
ZA202202370B (en) Compositions and methods for treating viral infections
PH12020551944A1 (en) Reverse peptide vaccine
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
WO2019039781A3 (ko) 신규한 에로모나스 살모니시다 박테리오파지 ａｅｒ-ｓａｐ-2 및 이의 에로모나스 살모니시다 균 증식 억제 용도
WO2018236086A3 (ko) 신규한 에로모나스 하이드로필라 박테리오파지 Aer-HYP-2 및 이의 에로모나스 하이드로필라 균 증식 억제 용도
MX2022010926A (es) Compuestos para su uso en infecciones viricas.
WO2018117462A3 (ko) 신규한 비브리오 파라헤몰리티쿠스 박테리오파지 Ｖｉｂ-ＰＡＰ-4 및 이의 비브리오 파라헤몰리티쿠스 균 증식 억제 용도
MX2021015961A (es) Moleculas novedosas.
WO2018127719A3 (en) Novel proteins and use thereof